BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31

BridgeBio Pharma, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$67.94+1.55 (+2.33%)

Close on Oct 19, 2026

Market cap: $13.30B
P/E (TTM): –
Dividend yield: –

BridgeBio Pharma, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Cash & Equivalents	570	681	376	377	394	356	364	436	92	–
Short-Term Investments	17	0	0	52	394	251	182	–	–	–
Cash & Short-Term Investments	587	681	376	428	788	607	546	436	92	–
Receivables	139	4.72	1.75	–	–	–	–	–	–	–
Inventory	27	0	–	–	–	–	–	–	–	–
Prepaid Expenses & Other	44	35	24	22	32	36	20	9.14	–	–
Other Current Assets	–	–	–	–	–	–	–	2.05	–	–
Total Current Assets	798	721	478	549	889	643	569	445	–	–
Property, Plant & Equipment	5.37	7.01	12	15	30	20	5.63	1.58	–	–
Long-Term Investments	–	–	–	–	–	–	31	–	–	–
Equity Method Investments	80	144	–	–	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	8.15	5.77	8.03	11	16	17	10	–	–	–
Intangible Assets	28	24	26	29	45	0	–	–	–	–
Other Long-Term Assets	17	18	23	20	33	24	26	1.09	–	–
Total Assets	936	919	546	623	1,013	704	632	465	–	–
Accounts Payable	36	9.62	11	12	12	8.95	8.85	14	–	–
Accrued Expenses	–	–	–	–	–	–	3.02	2.10	–	–
Current Portion of Long-Term Debt	–	–	–	–	–	1.46	–	–	–	–
Current Debt	–	–	–	–	–	1.46	–	–	–	–
Current Portion of Leases	6.19	4.51	4.13	3.68	4.94	3.80	8.00	–	–	–
Current Income Taxes Payable	–	1.15	–	–	–	–	–	–	–	–
Deferred Revenue (Current)	7.19	15	6.10	8.16	0	–	–	–	–	–
Other Current Liabilities	120	33	–	–	–	–	–	–	–	–
Total Current Liabilities	288	154	144	121	135	96	60	33	–	–
Long-Term Debt	–	437	446	431	431	92	92	55	–	–
Long-Term Leases	3.81	4.70	8.98	12	17	15	–	–	–	–
Operating Lease Liabilities	10	9.20	13	16	22	18	8.00	–	–	–
Other Long-Term Liabilities	0.24	0.29	5.63	27	22	9.52	3.53	0.50	–	–
Total Liabilities	3,013	2,377	1,889	1,868	1,878	596	156	88	–	–
Total Debt	–	437	446	431	431	94	92	55	–	–
Preferred Stock	0	0	–	–	–	–	–	–	–	–
Common Stock	0.20	0.20	0.18	0.16	0.15	0.13	0.12	0.09	0.05	0.02
Additional Paid-In Capital	2,058	1,903	1,481	939	842	1,021	848	494	134	33
Retained Earnings	-3,821	-3,096	-2,561	-1,918	-1,437	-889	-440	-179	-49	-18
Treasury Stock	-323	-275	-275	-275	-275	-75	–	–	–	–
Comprehensive Income & Other	0.01	0.01	0.03	-0.33	-0.13	0.19	0.25	–	–	–
Shareholders' Equity	-2,087	-1,468	-1,354	-1,255	-870	58	408	315	86	15
Noncontrolling Interest	11	10	11	11	3.41	48	65	62	2.50	2.60
Total Equity	-2,076	-1,458	-1,343	-1,243	-867	106	474	377	88	17
Total Liabilities & Equity	936	919	546	623	1,013	704	632	465	–	–
Shares Outstanding(shares)	195	190	175	151	147	123	124	92	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 94.4%
Operating margin: -69.8%
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 1.23
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 76.1%

Valuation

P/E ratio: –
Price to sales: 18.65
Price to book: –
Dividend yield: –